Greenwich LifeSciences, Inc. Price/Book Ratio
The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.
- Greenwich LifeSciences, Inc. price/book ratio for the quarter ending 2026-06-30 was 110.43, a 45.27% decline year-over-year.
- Greenwich LifeSciences, Inc. price/book ratio for the quarter ending 2026-03-31 was 67.05, a 89.32% decline year-over-year.
- Greenwich LifeSciences, Inc. price/book ratio for the quarter ending 2025-12-31 was 861.02, a 429.67% increase year-over-year.
- Greenwich LifeSciences, Inc. price/book ratio for the quarter ending 2025-09-30 was 62.63, a 65.21% increase year-over-year.
- Greenwich LifeSciences, Inc. price/book ratio for fiscal 2026 was 110.43.
- Greenwich LifeSciences, Inc. price/book ratio for fiscal 2025 was 861.02, a 429.67% increase from fiscal 2024.
- Greenwich LifeSciences, Inc. price/book ratio for fiscal 2024 was 162.56, a 705.85% increase from fiscal 2023.
- Greenwich LifeSciences, Inc. price/book ratio for fiscal 2023 was 20.17, a 36.49% increase from fiscal 2022.
- Available history
- 2020-09-30 to 2026-06-30
- Data captured
Historical Price/Book Ratio
Annual Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |